Development of a Mouse-Adapted Live Attenuated Influenza Virus That Permits<i>In Vivo</i>Analysis of Enhancements to the Safety of Live Attenuated Influenza Virus Vaccine

Abstract excerpt

The live attenuated influenza virus vaccine (LAIV) is preferentially recommended for use in persons 2 through 49 years of age but has not been approved for children under 2 or asthmatics due to safety concerns. Therefore, increasing safety is desirable. Here we describe a murine LAIV with reduced pathogenicity that retains lethality at high doses and further demonstrate that we can enhance safety in vivo through...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Influenza Virus Research Studies
• Share to Protein Structure and Dynamics
• Share to Receptor Mechanisms and Signaling